Ed Arce
Stock Analyst at HC Wainwright & Co.
(2.94)
# 1,232
Out of 4,412 analysts
285
Total ratings
34.88%
Success rate
0.92%
Average return
Main Sectors:
Top Industries:
34 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Buy | $17 → $19 | $5.26 | +261.22% | 15 | Apr 24, 2024 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $11 | $3.45 | +218.84% | 9 | Apr 9, 2024 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $120 | $12.63 | +850.12% | 17 | Apr 8, 2024 | |
| GNFT Genfit | Reiterates: Buy | $11 | $3.49 | +215.19% | 10 | Apr 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $58 | $24.46 | +137.12% | 21 | Apr 2, 2024 | |
| ITRM Iterum Therapeutics | Reiterates: Buy | $6 | $1.67 | +259.28% | 6 | Apr 1, 2024 | |
| IVA Inventiva | Reiterates: Buy | $22 | $3.25 | +576.92% | 11 | Apr 1, 2024 | |
| ASMB Assembly Biosciences | Reiterates: Neutral | n/a | $12.65 | - | 3 | Apr 1, 2024 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $4.5 | $1.03 | +336.89% | 14 | Apr 1, 2024 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $5 → $6 | $1.34 | +347.76% | 20 | Mar 28, 2024 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $0.93 | - | 7 | Mar 28, 2024 | |
| ETNB 89bio | Maintains: Buy | $31 | $8.26 | +275.30% | 14 | Mar 27, 2024 | |
| ZVSA ZyVersa Therapeutics | Reiterates: Buy | $12 | $4.89 | +145.40% | 4 | Mar 26, 2024 | |
| SYBX Synlogic | Upgrades: Neutral | n/a | $1.87 | - | 8 | Mar 20, 2024 | |
| ACXP Acurx Pharmaceuticals | Maintains: Buy | $14 → $12 | $2.07 | +479.71% | 10 | Mar 19, 2024 | |
| TERN Terns Pharmaceuticals | Reiterates: Neutral | $5.5 | $4.91 | +12.02% | 7 | Mar 15, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $405 → $425 | $193.33 | +119.83% | 11 | Mar 15, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $26.55 | +125.99% | 17 | Mar 8, 2024 | |
| TLPH Talphera | Reiterates: Buy | $6 | $1.05 | +471.43% | 2 | Mar 7, 2024 | |
| AKRO Akero Therapeutics | Maintains: Buy | $43 → $50 | $19.74 | +153.29% | 14 | Mar 5, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Buy | $13 | $4.91 | +164.77% | 11 | Mar 1, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $6 → $5 | $2.73 | +83.15% | 13 | Mar 1, 2024 | |
| PLRX Pliant Therapeutics | Reiterates: Buy | $48 | $11.81 | +306.44% | 13 | Feb 28, 2024 | |
| VERA Vera Therapeutics | Reiterates: Buy | $25 | $39.65 | -36.95% | 7 | Dec 27, 2023 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $30 → $28 | $12.37 | +126.35% | 6 | Nov 21, 2023 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $11 | $6.42 | +71.34% | 3 | Nov 1, 2023 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Buy | $82 | $44.24 | +85.35% | 2 | Aug 1, 2023 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Neutral | n/a | $0.39 | - | 2 | May 3, 2022 | |
| SMMT Summit Therapeutics | Initiates: Buy | n/a | $3.86 | - | 1 | Mar 19, 2020 | |
| TRVN Trevena | Downgrades: Neutral | n/a | $0.39 | - | 3 | Nov 5, 2018 | |
| ATXI Avenue Therapeutics | Initiates: Buy | n/a | $6.20 | - | 1 | Jun 25, 2018 | |
| VKTX Viking Therapeutics | Assumes: Buy | n/a | $74.31 | - | 1 | Nov 10, 2017 | |
| COLL Collegium Pharmaceutical | Initiates: Buy | n/a | $36.42 | - | 1 | Sep 11, 2017 | |
| AVIR Atea Pharmaceuticals | Downgrades: Neutral | n/a | $3.71 | - | 1 | Feb 15, 2017 |
Travere Therapeutics
Apr 24, 2024
Maintains: Buy
Price Target: $17 → $19
Current: $5.26
Upside: +261.22%
Galectin Therapeutics
Apr 9, 2024
Reiterates: Buy
Price Target: $11
Current: $3.45
Upside: +218.84%
Cidara Therapeutics
Apr 8, 2024
Maintains: Buy
Price Target: $120
Current: $12.63
Upside: +850.12%
Genfit
Apr 5, 2024
Reiterates: Buy
Price Target: $11
Current: $3.49
Upside: +215.19%
Mirum Pharmaceuticals
Apr 2, 2024
Maintains: Buy
Price Target: $58
Current: $24.46
Upside: +137.12%
Iterum Therapeutics
Apr 1, 2024
Reiterates: Buy
Price Target: $6
Current: $1.67
Upside: +259.28%
Inventiva
Apr 1, 2024
Reiterates: Buy
Price Target: $22
Current: $3.25
Upside: +576.92%
Assembly Biosciences
Apr 1, 2024
Reiterates: Neutral
Price Target: n/a
Current: $12.65
Upside: -
Unicycive Therapeutics
Apr 1, 2024
Reiterates: Buy
Price Target: $4.5
Current: $1.03
Upside: +336.89%
Akebia Therapeutics
Mar 28, 2024
Maintains: Buy
Price Target: $5 → $6
Current: $1.34
Upside: +347.76%
DURECT
Mar 28, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.93
Upside: -
89bio
Mar 27, 2024
Maintains: Buy
Price Target: $31
Current: $8.26
Upside: +275.30%
ZyVersa Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $12
Current: $4.89
Upside: +145.40%
Synlogic
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.87
Upside: -
Acurx Pharmaceuticals
Mar 19, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $2.07
Upside: +479.71%
Terns Pharmaceuticals
Mar 15, 2024
Reiterates: Neutral
Price Target: $5.5
Current: $4.91
Upside: +12.02%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $405 → $425
Current: $193.33
Upside: +119.83%
Arcturus Therapeutics Holdings
Mar 8, 2024
Reiterates: Buy
Price Target: $60
Current: $26.55
Upside: +125.99%
Talphera
Mar 7, 2024
Reiterates: Buy
Price Target: $6
Current: $1.05
Upside: +471.43%
Akero Therapeutics
Mar 5, 2024
Maintains: Buy
Price Target: $43 → $50
Current: $19.74
Upside: +153.29%
Aurinia Pharmaceuticals
Mar 1, 2024
Reiterates: Buy
Price Target: $13
Current: $4.91
Upside: +164.77%
Arbutus Biopharma
Mar 1, 2024
Maintains: Buy
Price Target: $6 → $5
Current: $2.73
Upside: +83.15%
Pliant Therapeutics
Feb 28, 2024
Reiterates: Buy
Price Target: $48
Current: $11.81
Upside: +306.44%
Vera Therapeutics
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $39.65
Upside: -36.95%
Enanta Pharmaceuticals
Nov 21, 2023
Maintains: Buy
Price Target: $30 → $28
Current: $12.37
Upside: +126.35%
Ardelyx
Nov 1, 2023
Maintains: Buy
Price Target: $9 → $11
Current: $6.42
Upside: +71.34%
Ultragenyx Pharmaceutical
Aug 1, 2023
Reiterates: Buy
Price Target: $82
Current: $44.24
Upside: +85.35%
Galmed Pharmaceuticals
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.39
Upside: -
Summit Therapeutics
Mar 19, 2020
Initiates: Buy
Price Target: n/a
Current: $3.86
Upside: -
Trevena
Nov 5, 2018
Downgrades: Neutral
Price Target: n/a
Current: $0.39
Upside: -
Avenue Therapeutics
Jun 25, 2018
Initiates: Buy
Price Target: n/a
Current: $6.20
Upside: -
Viking Therapeutics
Nov 10, 2017
Assumes: Buy
Price Target: n/a
Current: $74.31
Upside: -
Collegium Pharmaceutical
Sep 11, 2017
Initiates: Buy
Price Target: n/a
Current: $36.42
Upside: -
Atea Pharmaceuticals
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.71
Upside: -